Patients reconstructed with DermACELL as compared to AlloDerm RTU have significantly decreased number of days to drain removal and ‘red breast’ syndrome. Rates of other complications including seroma, infection, flap necrosis and explantation were equivalent.
An article recently accepted and made available online by Plastic and Reconstructive Surgery compared the clinical outcomes between two acellular dermal matrices (ADM): Dermacell and AlloDerm RTU in breast reconstruction.
Fifty-eight patients (100 breasts) were reconstructed using either Dermacell (n=30 patients; 50 breasts) or AlloDerm RTU (n=28 patients; 50 breasts). The reconstructions were performed by the same surgeon and the average age, BMI, percent having neo-adjuvant/adjuvant chemotherapy or breast irradiation, and numbers of therapeutic and prophylactic mastectomies between the two patient groups was not statistically significant (p<0.05).
Complications in both groups were recorded for 90 days post immediate reconstruction. The authors reported that patients in the Dermacell group had significantly less incidence of ‘red breast syndrome’ (0% vs 26%, p=0.0001) and fewer days before drain removal (15.8 vs 20.6, p=0.017) compared with the AlloDerm group. Additionally, no significant difference was seen in terms of seroma, hematoma, delayed healing, infection, flap necrosis, and explantation.
*Study projected to be published in March 2017 edition of The Journal of Plastic Reconstructive Surgery (PRS)*
Pittman, Troy A MD; et al. “Comparison of Different Acellular Dermal Matrices (ADM) in Breast Reconstruction: The 50/50 Study.” Plastic and Reconstructive Surgery(2016): n. pag. Web.